Australia spent the better part of a decade pouring money into digital health. The My Health Record initiative consumed over $2 billion before stabilising. Private hospital chains rolled out electronic medical record platforms costing tens of millions each. State health departments funded successive waves of digitisation programs. By any reasonable measure, the sector should be in a stronger position than it was in 2015.

It isn’t, at least not where it matters most. Healthtech startups attempting to build products that span more than one hospital system, one state, or one care setting are running into the same wall they hit five years ago: Australia’s health data infrastructure is profoundly fragmented, and the standards that exist on paper aren’t consistently implemented in practice.

The Optimistic Story Versus the Reality

The optimistic story goes like this. FHIR (Fast Healthcare Interoperability Resources) is the global standard. Australia adopted FHIR-AU. The Australian Digital Health Agency has been actively promoting standards adoption. Therefore, in 2026, healthtech companies should be able to build solutions that work across providers.

The reality, as told by founders at over a dozen Australian healthtech startups interviewed for this piece, is considerably messier. FHIR adoption varies wildly between jurisdictions and even between hospitals within the same Local Health District. Where FHIR is implemented, it’s often a partial implementation that covers specific use cases but leaves others to legacy HL7 v2 messaging or, in some cases, manual processes.

“I had a meeting last month with a hospital that proudly told me they’re FHIR-ready,” one founder said. “When we got into the details, they meant they had a FHIR endpoint that returned three resource types. We needed eight.”

The pattern repeats across the sector. The standards exist. Implementation is patchy. Coordination is essentially absent.

Why This Is Hurting the Sector Now Specifically

This isn’t a new problem. What’s changed is the maturity of the startups trying to deal with it.

Five years ago, most Australian healthtech startups were doing things that didn’t require deep integration—patient-facing apps, simple telehealth platforms, point solutions that ran alongside but not within existing clinical systems. Integration was hard, but it wasn’t critical to the value proposition.

The companies raising serious capital in 2025 and 2026 are different. They’re building AI-powered clinical decision support tools, population health analytics platforms, care coordination products, and remote monitoring solutions that span multiple care settings. All of these depend fundamentally on data flowing reliably between systems.

When the data doesn’t flow, the product doesn’t work. And the founders are discovering that the standards-versus-implementation gap is the single largest predictor of whether a healthtech deal closes.

SmartCompany reported in April 2026 that at least four Series B-stage Australian healthtech companies have either pivoted away from cross-provider products or scaled back their Australian go-to-market plans in favour of markets with more consistent infrastructure—primarily the US, Singapore, and parts of Northern Europe.

The Workarounds Are Becoming Industries

A small but growing category of Australian companies has emerged whose entire value proposition is solving the interoperability problem for everyone else.

Brisbane-based Alcidion has built a substantial business positioning its Miya Precision platform as an integration layer. Tasmanian startup Telstra Health, despite its enterprise scale, has effectively become an interoperability vendor for parts of its customer base. Smaller players including Strata Health, Cyber-Rx, and several others are competing in what’s increasingly a recognised category.

This is good for those companies. It’s less good for the broader sector, because it means health systems are paying integration costs to commercial vendors rather than addressing the underlying standards adoption problem.

The Australian Digital Health Agency has acknowledged the gap. Its 2025-2027 interoperability strategy explicitly identifies inconsistent implementation as the priority problem, and there’s been visible activity on conformance testing and provider engagement. Whether that translates to actual implementation progress remains to be seen.

What the Funders Are Saying

Venture capital appetite for Australian healthtech remains positive in aggregate, but the sub-sector matters enormously. Companies positioned as integration-light—diagnostic AI, patient engagement, administrative automation—are raising readily. Companies whose product requires data from multiple sources are facing harder questions in due diligence.

Several Australian VCs interviewed described having internal heuristics like “we don’t fund anything that requires three or more EMR integrations in Year 1” or “we want to see a real customer with the integration working before we lead a round.”

International funders are more skeptical still. A US-based health-tech investor described Australia as “a market where the unit economics look great on paper and disastrous after you’ve spent eighteen months integrating with one health network.”

What Would Actually Change the Picture

Three things would meaningfully shift the trajectory.

The first is procurement-driven standards enforcement. State health departments could mandate specific FHIR resource coverage as a condition of EMR contracts at renewal. This has been discussed but not yet implemented at scale.

The second is conformance testing with teeth. Currently, claiming FHIR compatibility carries no enforcement burden. A national conformance program with public reporting would change incentives quickly.

The third is funding for the integration work itself. The current model expects providers to fund their own standards implementation, which is rarely a clinical priority. Targeted federal funding for FHIR implementation, similar to the Practice Incentives Program model, could accelerate progress.

None of these are technically difficult. All of them require political and institutional commitment that hasn’t quite materialised at the scale needed.

The Outlook Through 2027

Healthtech founders are pragmatic about the situation. Several described running parallel strategies—building for the Australian market while staging international expansion to mitigate dependence on local infrastructure progress.

That’s probably the right call commercially. It’s also a missed opportunity for Australia, which has many of the underlying advantages—universal health coverage, a relatively small number of large providers, strong clinical research base—needed to be a global leader in digital health rather than a follower. Bridging the gap from “standards adopted” to “standards consistently implemented” is what stands between the current reality and that potential.

Through 2027, expect more startups to choose international-first strategies, more consolidation in the integration vendor space, and continued slow progress on the underlying problem. The companies that survive the gap will be substantial. Many that don’t survive it will have had products that, in a more functional infrastructure environment, would have worked beautifully.

For an outside view on how some of these companies are sequencing their integration and AI work, we’ve spoken to founders who’ve engaged an AI consultancy (Team400) on architecture decisions where getting the data plumbing right matters more than the model choice.